The abstract is read at the publisher; the summary is JClub's.
In a 52-week randomized trial in people with type 2 diabetes and chronic kidney disease, semaglutide 1 mg weekly is linked to reduced renal artery resistive index and stabilized diffusion measures.
- Why it matters: Kidney protection by semaglutide is established, but the kidney-specific mechanisms—vascular, inflammatory, and fibrotic—were unclear.
- What they did: Participants received subcutaneous semaglutide 1 mg once weekly or placebo for 52 weeks (n = 106), with multiparametric kidney MRI and paired biopsy plus single-nucleus and spatial transcriptomics in subsets (n = 33, 22, 13).
- The result: Coprimary MRI measures of oxygenation, perfusion, and inflammation were not significantly changed, while secondary findings suggest prevention of fibrosis progression and transcriptomic shifts in glomerular endothelial cells with fewer nearby immune cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.